首页> 外国专利> FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

机译:法呢基转移酶抑制了被N或C键联的咪唑取代的1,8-基喹啉酮衍生物,其制备方法和组成它们的药物成分

摘要

Anticancer compounds of the formula pharmaceutically acceptable acid addition salts or stereochemically isomeric forms thereof, wherein the dotted line is null if R' is H, and otherwise represents an optional bond, X is oxygen or sulfur; -A- is a bivalent radical of the formula -CH=CH--CH2-S- -CH2-CH2--CH2-CH2-S- -CH2-CH2-CH2-CH=N- -CH2-O--N=N- -CH2-CH2-O--CO-NH- 3647 כ" ז בשבט התשס" ד - February 19, 2004 wherein optionally one hydrogen atom may be replaced by C1-4 alkyl or Ar1; R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6 alkyl, trihalomethyl, trihalomethoxy, C2-6 alkenyl, C1-6 alkyloxy, hydroxy C1-6 alkyloxy, C1-6 alkyloxy C1-6 alkyloxy, C1-6 alkyloxycarbonyl, amino C1-6 alkyloxy, mono- or di(C1-6 alkyl) amino C1-6 alkyloxy, Ar2, Ar2-C1-6alkyl, Ar2-oxy, Ar2-C1-6 alkyloxy; or when on adjacent positions R1 and R2 taken together may form a bivalent radical of formula -O-CH2-O- -O-CH2-CH2-O- -O-CH=CH- -O-CH2-CH2- -O-CH2-CH2-CH2- -CH=CH-CH=CH- R3 and R4 each independently are hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkyloxy, Ar3-oxy, C1-6 alkylthio, di(C1-6 alkyl) amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R3 and R4 taken together may form a bivalent radical of the formula -O-CH2-O- -O-CH2-CH2-O- -CH=CH-CH=CH- R5 is a radical of the formula wherein R13 is hydrogen, halo, Ar4, C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkyloxy C1-6 alkyl, C1-6 alkyloxy, C1-6 alkylthio, amino, C1-6 alkyloxycarbonyl, C1-6 alkyl S(O)C1-6 alkyl or C1-6 alkyl S(O)2C1-6 alkyl; R14 is hydrogen, C1-6 alkyl or di(C1-4 alkyl) aminosulfonyl; R6 is hydrogen, hydroxy, halo, C1-6 alkyl, cyano, halo C1-6 alkyl, hydroxy C1-6 alkyl, cyano C1-6 alkyl, amino C1-6 alkyl, C1-6 alkyloxy C1-6 alkyl, C1-6 alkylthio C1-6 alkyl, aminocarbonyl-C1-6 alkyl, C1-6 alkyloxycarbonyl C1-6 alkyl, C1-6 alkylcarbonyl C1-6 alkyl, C1-6 alkyloxycarbonyl, mono- or di(C1-6 alkyl) amino C1-6 alkyl, Ar5, Ar5-C1-6 alkyloxy C1-6 alkyl; or a radical of the formula -O-R7 -S-R7 or -N-R8R9 wherein R7 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, Ar6, Ar6-C1-6 alkyl, C1-6 alkyloxycarbonyl C1-6 alkyl, or a radical of formula -Alk-OR10 or -Alk-NR11R12 R8 is hydrogen, C1-6 3648 כ" ז בשבט התשס" ד - February 19, 2004 alkyl, Ar7 or Ar7-C1-6 alkyl; R9 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, Ar8, Ar8-C1-6 alkyl, C1-6 alkylcarbonyl-C1-6 alkyl, Ar8-carbonyl, Ar8-C1-6 alkylcarbonyl, aminocarbonylcarbonyl, C1-6 alkyloxy C1-6 alkylcarbonyl, hydroxy, C1-6 alkyloxy, aminocarbonyl, di(C1-6 alkyl) amino C1-6 alkylcarbonyl, amino, C1-6 alkylamino, C1-6 alkylcarbonylamino, or a radical of formula -Alk-OR10 or -Alk-NR11R12; wherein Alk is C1-6 alkanediyl; R10 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, hydroxy C1-6 alkyl, Ar9 or Ar9-C1-6 alkyl; R11 is hydrogen, C1-6 alkyl, C1-6 alkylcarbonyl, Ar10 or Ar10C1-6 alkyl; R12 is hydrogen, C1-6 alkyl, Ar11 or Ar11-C1-6 alkyl; and Ar1 to Ar11 are each independently selected from phenyl; or phenyl substituted with halo, C1-6 alkyl, C1-6 alkyloxy or trifluoromethyl; wherein R' is H,
机译:式药学上可接受的酸加成盐或其立体化学异构体形式的抗癌化合物,其中如果R'为H,则虚线为空,否则代表任选的键,X为氧或硫; -A-是式-CH = CH--CH2-S- -CH2-CH2--CH2-CH2-S- -CH2-CH2-CH2-CH = N- -CH2-O-N的二价基团= N--CH 2 -CH 2 -O-CO-NH-3647-2004年2月19日,其中任选一个氢原子可以被C 1-4烷基或Ar 1取代; R 1和R 2各自独立地是氢,羟基,卤素,氰基,C 1-6烷基,三卤甲基,三卤甲氧基,C 2-6烯基,C 1-6烷氧基,羟基C 1-6烷氧基,C 1-6烷氧基,C 1-6烷氧基,C 1- 6烷氧基羰基,氨基C 1-6烷氧基,单或二(C 1-6烷基)氨基C 1-6烷氧基,Ar 2,Ar 2 -C 1-6烷基,Ar 2氧基,Ar 2 -C 1-6烷氧基;或当在相邻的位置R1和R2在一起时可形成式-O-CH2-O- -O-CH2-CH2-O- -O-CH = CH- -O-CH2-CH2- -O-的二价基团CH 2 -CH 2 -CH 2 --CH = CH-CH = CH- R 3和R 4各自独立地是氢,卤素,氰基,C 1-6烷基,C 1-6烷氧基,Ar 3氧基,C 1-6烷硫基,二(C 1- 6烷基)氨基,三卤代甲基,三卤代甲氧基,或当在相邻位置R3和R4一起时可形成式为-O-CH2-O- -O-CH2-CH2-O- -CH = CH-CH =的二价基团CH-R5是下式的基团,其中R13是氢,卤素,Ar4,C1-6烷基,羟基C1-6烷基,C1-6烷氧基C1-6烷基,C1-6烷氧基,C1-6烷硫基,氨基, C 1-6烷氧基羰基,C 1-6烷基S(O)C 1-6烷基或C 1-6烷基S(O)2 C 1-6烷基; R14是氢,C1-6烷基或二(C1-4烷基)氨基磺酰基; R 6是氢,羟基,卤素,C 1-6烷基,氰基,卤素C 1-6烷基,羟基C 1-6烷基,氰基C 1-6烷基,氨基C 1-6烷基,C 1-6烷氧基C 1-6烷基,C 1- 6烷硫基C1-6烷基,氨基羰基-C1-6烷基,C1-6烷氧基羰基C1-6烷基,C1-6烷基羰基C1-6烷基,C1-6烷氧基羰基,单或二(C1-6烷基)氨基C1- 6烷基,Ar5,Ar5-C1-6烷氧基C1-6烷基;或式-O-R7-S-R7或-N-R8R9的基团,其中R7是氢,C1-6烷基,C1-6烷基羰基,Ar6,Ar6-C1-6烷基,C1-6烷氧基羰基C1-6烷基,或式-Alk-OR10或-Alk-NR11R12 R8的基团是氢,C 1-6 3648烷基-2004年2月19日烷基,Ar 7或Ar 7 -C 1-6烷基; R 9为氢,C 1-6烷基,C 1-6烷基羰基,C 1-6烷氧基羰基,C 1-6烷基氨基羰基,Ar 8,Ar 8 -C 1-6烷基,C 1-6烷基羰基-C 1-6烷基,Ar 8羰基,Ar 8 -C 1 -6烷基羰基,氨基羰基羰基,C1-6烷氧基C1-6烷基羰基,羟基,C1-6烷氧基,氨基羰基,二(C1-6烷基)氨基C1-6烷基羰基,氨基,C1-6烷基氨基,C1-6烷基羰基氨基或式-Alk-OR10或-Alk-NR11R12的基团;其中Alk是C 1-6烷二基; R10为氢,C1-6烷基,C1-6烷基羰基,羟基C1-6烷基,Ar9或Ar9-C1-6烷基; R11是氢,C1-6烷基,C1-6烷基羰基,Ar10或Ar10C1-6烷基; R12为氢,C1-6烷基,Ar11或Ar11-C1-6烷基; Ar1〜Ar11分别独立地选自苯基。或被卤素,C 1-6烷基,C 1-6烷氧基或三氟甲基取代的苯基;或其中R'为H,

著录项

  • 公开/公告号IL130362B

    专利类型

  • 公开/公告日2004-02-19

    原文格式PDF

  • 申请/专利权人 JANSSEN PHARMACEUTICA N.V.;

    申请/专利号IL130362

  • 发明设计人

    申请日1998-03-03

  • 分类号C07D471/06;A61K31/395;A61P35/00;C07D498/06;C07D513/06;

  • 国家 IL

  • 入库时间 2022-08-21 23:10:43

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号